358 related articles for article (PubMed ID: 16052206)
1. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
[TBL] [Abstract][Full Text] [Related]
2. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
[TBL] [Abstract][Full Text] [Related]
3. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
Hackett NR; Redmond DE; Sondhi D; Giannaris EL; Vassallo E; Stratton J; Qiu J; Kaminsky SM; Lesser ML; Fisch GS; Rouselle SD; Crystal RG
Hum Gene Ther; 2005 Dec; 16(12):1484-503. PubMed ID: 16390279
[TBL] [Abstract][Full Text] [Related]
4. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system.
Haskell RE; Hughes SM; Chiorini JA; Alisky JM; Davidson BL
Gene Ther; 2003 Jan; 10(1):34-42. PubMed ID: 12525835
[TBL] [Abstract][Full Text] [Related]
5. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
[TBL] [Abstract][Full Text] [Related]
6. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.
Sondhi D; Hackett NR; Peterson DA; Stratton J; Baad M; Travis KM; Wilson JM; Crystal RG
Mol Ther; 2007 Mar; 15(3):481-91. PubMed ID: 17180118
[TBL] [Abstract][Full Text] [Related]
7. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
Worgall S; Sondhi D; Hackett NR; Kosofsky B; Kekatpure MV; Neyzi N; Dyke JP; Ballon D; Heier L; Greenwald BM; Christos P; Mazumdar M; Souweidane MM; Kaplitt MG; Crystal RG
Hum Gene Ther; 2008 May; 19(5):463-74. PubMed ID: 18473686
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Bernardini F; Warburton MJ
Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
[TBL] [Abstract][Full Text] [Related]
9. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
Sondhi D; Peterson DA; Edelstein AM; del Fierro K; Hackett NR; Crystal RG
Exp Neurol; 2008 Sep; 213(1):18-27. PubMed ID: 18639872
[TBL] [Abstract][Full Text] [Related]
10. Expression and analysis of CLN2 variants in CHO cells: Q100R represents a polymorphism, and G389E and R447H represent loss-of-function mutations.
Lin L; Lobel P
Hum Mutat; 2001 Aug; 18(2):165. PubMed ID: 11462245
[TBL] [Abstract][Full Text] [Related]
11. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
[TBL] [Abstract][Full Text] [Related]
12. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.
Worgall S; Kekatpure MV; Heier L; Ballon D; Dyke JP; Shungu D; Mao X; Kosofsky B; Kaplitt MG; Souweidane MM; Sondhi D; Hackett NR; Hollmann C; Crystal RG
Neurology; 2007 Aug; 69(6):521-35. PubMed ID: 17679671
[TBL] [Abstract][Full Text] [Related]
13. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis.
Kopan S; Sivasubramaniam U; Warburton MJ
Biochem Biophys Res Commun; 2004 Jun; 319(1):58-65. PubMed ID: 15158442
[TBL] [Abstract][Full Text] [Related]
14. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
[TBL] [Abstract][Full Text] [Related]
15. R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis.
Barisić N; Logan P; Pikija S; Skarpa D; Blau N
Croat Med J; 2003 Aug; 44(4):489-93. PubMed ID: 12950156
[TBL] [Abstract][Full Text] [Related]
16. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis.
Griffey M; Macauley SL; Ogilvie JM; Sands MS
Mol Ther; 2005 Sep; 12(3):413-21. PubMed ID: 15979943
[TBL] [Abstract][Full Text] [Related]
17. Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.
Tsiakas K; Steinfeld R; Storch S; Ezaki J; Lukacs Z; Kominami E; Kohlschütter A; Ullrich K; Braulke T
Glycobiology; 2004 Apr; 14(4):1C-5C. PubMed ID: 14736728
[TBL] [Abstract][Full Text] [Related]
18. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
Ezaki J; Takeda-Ezaki M; Oda K; Kominami E
Biochem Biophys Res Commun; 2000 Feb; 268(3):904-8. PubMed ID: 10679303
[TBL] [Abstract][Full Text] [Related]
19. Structural organization and sequence of CLN2, the defective gene in classical late infantile neuronal ceroid lipofuscinosis.
Liu CG; Sleat DE; Donnelly RJ; Lobel P
Genomics; 1998 Jun; 50(2):206-12. PubMed ID: 9653647
[TBL] [Abstract][Full Text] [Related]
20. Tripeptidyl-peptidase I in health and disease.
Golabek AA; Kida E
Biol Chem; 2006 Aug; 387(8):1091-9. PubMed ID: 16895480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
